Real-world treatment satisfaction with teriflunomide: results from the European cohort of the phase 4 Teri-PRO study

被引：0

作者：

Vermersch, P. ^{[1
]}

Meca Lallana, J. ^{[2
]}

Maida, E.

van Pesch, V. ^{[3
]}

Kuusisto, H. ^{[4
]}

Comi, G. ^{[5
]}

Johansson, R. ^{[6
]}

Rashid, W. ^{[7
]}

Fakas, N. ^{[8
]}

Rufi, P. ^{[9
]}

Poole, E. ^{[10
]}

Gold, R. ^{[11
]}

机构：

[1] Univ Lille, Lille, France

[2] UCAM Univ Catolica San Antonio Murcia, Hosp Virgen de la Arrixaca, Murcia, Spain

[3] Catholic Univ Louvain, Clin Univ St Luc, Brussels, Belgium

[4] Kanta Hame Cent Hosp, Hameenlinna, Finland

[5] Univ Vita Salute San Raffaele, Milan, Italy

[6] Cent Sjukhuset, Karlstad, Sweden

[7] Royal Sussex Cty Hosp, Brighton, E Sussex, England

[8] 401 Gen Mil Hosp Athens, Athens, Greece

[9] Sanofi Genzyme, Chilly Mazarin, France

[10] Sanofi Genzyme, Cambridge, MA USA

[11] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany

来源：

MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EP1650

引用

页码：868 / 869

页数：2

共 50 条

[1] Teriflunomide real-world safety profile: results of the Phase 4 Teri-PRO Study
Coyle, P. K.
Khatri, B.
Edwards, K. R.
Meca Lallana, J.
Cavalier, S.
Rufi, P.
Benamor, M.
Brette, S.
Gold, R.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 308 - 309
[2] Impact of teriflunomide treatment on real-world quality of life in the Phase 4 Teri-PRO Study
Gold, R.
Khatri, B.
Edwards, K. R.
Cavalier, S.
Rufi, P.
Brette, S.
Coyle, P. K.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 307 - 308
[3] Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study
Coyle, Patricia K.
Khatri, Bhupendra
Edwards, Keith R.
Meca-Lallana, Jose E.
Cavalier, Steve
Rufi, Pascal
Benamor, Myriam
Poole, Elizabeth M.
Robinson, Miqun
Gold, Ralf
[J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 31 : 157 - 164
[4] Teriflunomide real-world outcomes in the phase 4 Teri-PRO Study: Results from Europe, Canada, and Latin America
Gold, R.
Khatri, B.
Edwards, K. R.
Cavalier, S.
Rufi, P.
Thangavelu, K.
Benamor, M.
Coyle, P. K.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 197 - 197
[5] Improvements in patient-reported treatment satisfaction with teriflunomide: results from the Phase 4 Teri-PRO Study
Coyle, P. K.
Khatri, B.
Edwards, K. R.
Cavalier, S.
Rufi, P.
Brette, S.
Gold, R.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 774 - 775
[6] Treatment satisfaction across age groups in patients who switched to teriflunomide: analysis of the real-world teri-pro study
Coyle, P.
Gold, R.
De Seze, J.
Khatri, B.
Yamout, B.
Pyatkevich, Y.
Poole, E.
Vermersch, P.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 622 - 623
[7] Disability outcomes with teriflunomide: Results from the US and from Europe, Canada and Latin America in the real-world teri-PRO study
Gold, R.
Khatri, B.
Edwards, K. R.
Cavalier, S.
Rufi, P.
Thangavelu, K.
Benamor, M.
Coyle, P.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 495 - 495
[8] Lymphocyte Counts in Patients Treated With Teriflunomide: Observations From Phase 3 Clinical Trials and the Real-World Teri-PRO Study
Coyle, Patricia
Miller, Aaron
Gold, Ralf
Vermersch, Patrick
Khatri, Bhupendra
Benamor, Myriam
Chavin, Jeffrey
Thangavelu, Karthinathan
Comi, Giancarlo
[J]. NEUROLOGY, 2018, 90
[9] Clinical Outcomes And Treatment Satisfaction In Patients Switching To Teriflunomide In The Real-world Teri-PRO And TAURUS-MS I Studies
Freedman, M. S.
Kallmann, B. A.
Meca-Lallana, J. E.
Khatri, B.
Inshasi, J. S.
Kim, B. J.
Rufi, P.
Benamor, M.
Truffinet, P.
Poole, E. M.
Coyle, P. K.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 137 - 137
[10] Clinical outcomes and treatment satisfaction in patients switching to teriflunomide in the real-world Teri-PRO and TAURUS-MS I studies
Freedman, Mark S.
Kallmann, Boris A.
Meca-Lallana, Jose E.
Khatri, Bhupendra
Inshasi, Jihad Said
Rufi, Pascal
Benamor, Myriam
Truffinet, Philippe
Poole, Elizabeth M.
Coyle, Patricia K.
[J]. NEUROLOGY, 2020, 94 (15)

← 1 2 3 4 5 →